diphtheria, tetanus and whole cell pertussis vaccine
Trade name: Boostrix
Approved
May 3, 2005
The DPT vaccine or DTP vaccine is a class of combination vaccines to protect against three infectious diseases in humans: diphtheria, pertussis, and tetanus (lockjaw). The vaccine components include diphtheria and tetanus toxoids, and either killed whole cells of the bacterium that causes pertussis or pertussis antigens. The term toxoid refers to vaccines which use an inactivated toxin produced by the pathogen which they are targeted against to generate an immune response. In this way, the toxoid vaccine generates an immune response which is targeted against the toxin which is produced by the pathogen and causes disease, rather than a vaccine which is targeted against the pathogen itself. The whole cells or antigens will be depicted as either "DTwP" or "DTaP", where the lower-case "w" indicates whole-cell inactivated pertussis and the lower-case "a" stands for "acellular". In comparison to alternative vaccine types, such as live attenuated vaccines, the DTP vaccine does not contain any live pathogen, but rather uses inactivated toxoid to generate an immune response; therefore, there is not a risk of use in populations that are immune compromised since there is not any known risk of causing the disease itself. As a result, the DTP vaccine is considered a safe vaccine to use in anyone and it generates a much more targeted immune response specific for the pathogen of interest. — Wikipedia
Clinical trial activity
37 trials · 31 clinical orgs · 2 marketing orgs
Earliest trial started Jan 1, 2002 (NCT01277705)
Timeline
1940s
- Jul 1, 1948
Evidence of US Marketing
2000s
- Jan 1, 2002
GlaxoSmithKline — Earliest Phase 3 Sponsor(trial)
- May 3, 2005
GlaxoSmithKline — Earliest FDA Approval
- May 3, 2005
GlaxoSmithKline — NDA Secondary Org
- May 3, 2005
GlaxoSmithKline — NDA Organization
- Jun 10, 2005
Sanofi-Aventis — NDA Secondary Org
Indications
Approved for
Studied for
- Diphtheria · Phase 4
- Diphtheria-Tetanus-acellular Pertussis Vaccines · Phase 4
- Healthy Volunteers · Phase 1
- Herpes Zoster · Phase 3
- Immunization · Phase 4
- Meningitis · Phase 4
- Meningococcal Infections · Phase 4
- Papillomavirus Infections · Phase 3
- Pertussis Vaccine · Phase 4
- Poliomyelitis · Phase 4
- Respiratory Syncytial Virus Infections · Phase 3
- Rheumatic Diseases · Phase 4
- Tetanus · Phase 4
- Typhoid Fever · Phase 1
- Whooping Cough · Phase 4
Mechanism of action
- Clostridium tetaniImmunity, active
Clostridium tetani immunity, active
- Corynebacterium diphtheriaeImmunity, active
Corynebacterium diphtheriae immunity, active
- Diphtheria toxinImmunity, active
Diphtheria toxin immunity, active
- Bordetella pertussisImmunity, active
inactivated Bordetella pertussis immunity, active
- Tetanus toxinImmunity, active
tetX immunity, active
Approval history
- approvedMay 3, 2005
- withdrawnJul 1, 1948
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDPT vaccine ↗
Also known as
- boostrix
- dpt vaccin
- dtpa vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06997627 | Phase 1/Phase 2 (Phase 2) | Jun 5, 2025 | Green Cross Corporation |
| NCT05613205 | Phase 1 | Nov 8, 2022 | BE Pharmaceuticals, GlaxoSmithKline |
| NCT05543642 | Phase 4 | Oct 5, 2022 | Oregon Health and Science University |
| NCT05169905 | Phase 3 | Feb 2, 2022 | GlaxoSmithKline |
| NCT04138056 | Phase 2 | Nov 4, 2019 | GlaxoSmithKline |
| NCT04238975 | Phase 2 | Oct 14, 2019 | Green Cross Corporation |
| NCT03909126 | Phase 4 | May 31, 2019 | Government of France, St. Justine's Hospital |
| NCT03606096 | Phase 4 | Sep 30, 2018 | Imperial College London, Leiden University, National Institute for Public Health and the Environment, RIVM, Holland, Radboud University, University of London, University of Oxford, University of Turku |
| NCT03697798 | Phase 4 | Apr 18, 2018 | National Institute for Public Health and the Environment, RIVM, Holland, Spaarne Gasthuis, University of Oxford, University of Turku |
| NCT03311659 | Phase 3 | Jan 26, 2018 | GlaxoSmithKline |
| NCT02946190 | Phase 2 | Oct 27, 2016 | BioNet-Asia Co., Ltd., University of Geneva |
| NCT03035370 | Phase 1 | Sep 1, 2016 | DBV Technologies, University of Geneva |
| NCT02813486 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2016 | Green Cross Corporation |
| NCT02377349 | Phase 4 | Oct 14, 2015 | GlaxoSmithKline |
| NCT02543918 | Phase 1 | Sep 1, 2015 | Eli Lilly |
| NCT02555540 | Phase 4 | Aug 1, 2015 | deCODE genetics, European Commission, Ghent University, GlaxoSmithKline, Max Planck Institute, Novartis, Sanofi-Aventis, University of London |
| NCT02408926 | Phase 4 | Apr 1, 2015 | Chulalongkorn University, Institut Pasteur, Thrasher Research Fund, University of Antwerp |
| NCT02072525 | Phase 4 | Apr 1, 2014 | GlaxoSmithKline |
| NCT02052596 | Phase 3 | Feb 7, 2014 | GlaxoSmithKline |
| NCT01988857 | Phase 3 | Feb 1, 2014 | GlaxoSmithKline |
Organizations
Research & Development (31)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 23 | 22 | 4 | 2002 |
| Green Cross Corporation | For profit | 3 | 3 | 1 | 2016 |
| National Institute for Public Health and the Environment, RIVM, Holland | Government | 2 | 0 | 1 | 2018 |
| University of Geneva | Academic/Hospital | 2 | 1 | 2 | 2016 |
| University of London | Academic/Hospital | 2 | 1 | 1 | 2015 |
| University of Oxford | Academic/Hospital | 2 | 1 | 1 | 2018 |
| University of Turku | Academic/Hospital | 2 | 0 | 1 | 2018 |
| BE Pharmaceuticals | For profit | 1 | 0 | 1 | 2022 |
| BioNet-Asia Co., Ltd. | For profit | 1 | 0 | 1 | 2016 |
| Chulalongkorn University | Academic/Hospital | 1 | 0 | 1 | 2015 |
| DBV Technologies | For profit | 1 | 1 | 1 | 2016 |
| deCODE genetics | For profit | 1 | 0 | 1 | 2015 |
| Eli Lilly | For profit | 1 | 1 | 1 | 2015 |
| European Commission | Government | 1 | 0 | 1 | 2015 |
| Ghent University | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Government of France | Government | 1 | 0 | 1 | 2019 |
| Imperial College London | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Institut Pasteur | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Leiden University | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Max Planck Institute | Academic/Hospital | 1 | 0 | 1 | 2015 |
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| GlaxoSmithKline | For profit | NDA2 | May 3, 2005 |
| GlaxoSmithKline | For profit | NDA | May 3, 2005 |
| Sanofi-Aventis | For profit | NDA2 | Jun 10, 2005 |